-
Grand Pharmaceutical Group Reports Strong 2024 Financials with 12.8% Revenue Growth
•
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) revealed its 2024 financial performance, recording revenues of HKD 11.64 billion (USD 1.5 billion), marking a 12.8% year-on-year increase. Net profits reached HKD 2.47 billion (USD 318 million), up 34% from the previous year. Based on this strong performance, the company plans…
-
Ping An Healthcare Reports 2024 Financial Turnaround with Growth in Healthcare Services
•
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as Ping An Good Doctor, released its 2024 financial report. The company recorded RMB 4.8 billion (USD 664 million) in revenues, marking a 2.9% year-on-year (YOY) increase. Notably, Ping An Healthcare achieved a significant turnaround by posting RMB88.32…
-
Legend Biotech Reports Strong Q4 and Full Year 2024 Financial Results
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q4 and full-year 2024 financial results, highlighting significant revenue growth. In Q4, the company reported revenues of USD187 million, marking a 134.7% year-on-year increase. For the entire year, revenues surged by 120.0% to USD627 million. Carvykti’s Impact on RevenueThe BCMA-directed chimeric antigen…
-
MicroPort Scientific Corp. Reports 10% Revenue Growth and 58% Net Loss Decrease in 2024
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) released its 2024 full-year performance estimation. The company expects group revenues to increase by 10%, with the net loss staying below USD275 million, marking a 58% decrease from the same period last year. Overseas business revenues saw a significant surge of…
-
Merck KGaA Reports 2024 Revenue Growth Despite Challenges in Life Sciences
•
German major Merck KGaA (ETR: MRK) this week released its 2024 annual report, highlighting a mixed performance across its business segments. The company reported global revenues up 2.0% year-on-year (YoY) in organic terms to EUR 21.16 billion (USD 2.3 billion). The Healthcare unit drove growth, while the Life Sciences segment…
-
Sandoz’s Q4 2024 Results Show Strong Biosimilar Growth
•
Switzerland-headquartered Sandoz (SWX: SDZ) has released its Q4 2024 financial results. The firm’s global revenues rose 9% year-on-year (YOY) in constant currencies to USD 10.7 billion during the year. The firm’s performance improved during the year, with Q4 revenues up 9% YOY to USD 2.7 billion. Sales BreakdownGeneric drugs generated…
-
Bayer Posts Steady Q4 Growth, Pharmaceutical Sales Lead the Way
•
German giant Bayer (ETR: BAYN) has released its Q4 2024 financial results, reporting a 0.7% year-on-year (YOY) growth in constant currency terms, with global group sales for the twelve months reaching EUR 46.6 billion (USD 50.3 billion). Sales Performance by DivisionCrop Sciences sales declined by 2% to EUR 22.2 billion…
-
BeiGene’s Q4 and 2024 Financials Highlight Significant Growth and Product Success
•
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) released financial results and corporate updates from the fourth quarter and full year 2024 as the oncology biotech works to change its name to BeOne Medicines Ltd. The company recorded USD 1.128 billion in Q4 and USD 3.81 billion in 2024 revenues,…
-
Zai Lab Q2 and Full-Year 2024 Report Shows Sales Growth and Loss Reduction
•
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 and full-year 2024 financial report. The company recorded USD 108.5 million in product net sales in Q4 and USD 397.6 million for the full year of 2024, marking a 65% and 50% year-on-year (YOY) increase at constant exchange…
-
Viatris Q4 and Full-Year Results Show Greater China Growth
•
US generics giant Viatris (NASDAQ: VTRS) released its Q4 and full-year 2024 financial results. In the fourth quarter, revenues dropped 7% year-on-year (YOY) to USD 3.515 billion. However, the Greater China region generated USD 522 million in sales after a 2% expansion. For the whole year, company revenues stood at…
-
Dizal Pharma’s 2024 Revenues Surge 295% to RMB360M, Loss Narrows by RMB251M
•
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial preview, showing annual revenues jumped 294.79% year-on-year (YOY) to RMB360.4 million ($49.67 million). Net loss attributable to the parent company was RMB856.77 million ($118 million), down RMB250.94 million ($34.6 million) from 2023. Key Highlights
-
Ipsen Posts 8.7% Revenue Growth in 2024, Driven by Rare Diseases and Oncology
•
French biopharma firm Ipsen (EPA: IPN, OTCMKTS: IPSEY) reported an 8.7% year-on-year (YOY) increase in global revenues to €3.4 billion ($3.57 billion) for 2024, according to its annual financial report. Core operating profit rose 10.8% YOY to €1.109 billion ($1.165 billion), driven by strong performances across all business sectors. Sector…
-
Baxter International Reports Q4 2024 Revenues of USD 2.75B, Up 2% YOY
•
Baxter International (NYSE: BAX) announced its fourth-quarter 2024 financial results, reporting revenues of USD 2.75 billion, a 2% increase year-on-year (YOY). For the full year, revenues rose 3% YOY to USD 10.64 billion. Q4 Segment Performance Full-Year Segment Performance Kidney Care BusinessBaxter completed the sale of its Kidney Care business…
-
AstraZeneca Faces Class Action Lawsuits Over China Legal Issues
•
AstraZeneca plc (AZ, NASDAQ: AZN) is facing multiple class action lawsuits in the United States related to recent legal issues in China, including the arrest of its former China market president, Leon Wang. The lawsuits allege that the UK-based pharmaceutical giant made misleading statements about its operations in China, failing…
-
Medtronic Q3 Earnings Show 4.1% Organic Growth, Driven by Cardiac Ablation
•
US-Irish medical device company Medtronic (NYSE: MDT) reported financial results for the third quarter (Q3) of fiscal year 2025 (FY25), which ended on January 24, 2025. The company posted revenues of USD 8.3 billion, marking a 4.1% increase on an organic basis. Segment Performance OutlookMedtronic reiterated its organic revenue growth…
-
GE Healthcare Posts 1% Annual Revenue Growth in 2024 Financials
•
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) released its Q4 and full-year 2024 financial results. The company reported annual revenues of USD19.7 billion, representing a 1% year-on-year (YOY) growth in constant currency terms. Group revenues for Q4 grew by 2% YOY to USD5.3 billion.…
-
Trinomab’s Antitetanus mAb Injection TNM002 Approved by NMPA
•
China-based Trinomab Biotech Co., Ltd has received market approval for its antitetanus toxin monoclonal antibody (mAb) injection TNM002 from the National Medical Products Administration (NMPA). Product DetailsTNM002 is a Category 1 product, an iterated novel tetanus shot used for emergency prevention of tetanus in adults. It delivers emergency protection through…
-
Gilead Sciences’ Q4 2024 Financials Show 6% Revenue Growth, Driven by HIV and Oncology
•
Gilead Sciences Inc. (NASDAQ: GILD) reported a 6% year-on-year (YOY) increase in global revenues for Q4 2024, reaching USD 7.6 billion, driven by strong performance in HIV, oncology, and liver disease segments. Full-year revenues also rose 6% to USD 28.8 billion. Product Performance Geographical Breakdown Outlook for 2025Gilead plans to…
-
Siemens Healthineers Posts Strong Q1 Results with 5.7% Revenue Growth
•
Germany-based Siemens Healthineers AG (ETR: SHL) released its results for the first quarter of fiscal year 2025, ended December 31, 2024. The company showcased an excellent equipment book-to-bill ratio of 1.21 and comparable revenue growth of 5.7%. This marks a strong start to the fiscal year, driven by growth across…
-
Bristol-Myers Squibb Posts 8% Q4 Revenue Growth, Driven by Opdivo and New Products
•
Bristol-Myers Squibb (BMS, NYSE: BMY) reported an 8% year-on-year (YOY) increase in revenues to USD 12.3 billion during Q4 2024, excluding foreign exchange impact. For the full year, revenues rose 7% YOY to USD 48.3 billion, according to the company’s financial report released this week. The US market expanded 9%…
